

Notification of global End of Trial

Sponsor Study Number: D3252C00004

EudraCT Number: 2020-000195-38

Study title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Removal in Patients with Chronic Rhinosinusitis with Nasal Polyps (OXALIS)

Dear Sir/Madam,

With reference to the above clinical study, we hereby notify the agency of the end of trial for this global study. The OXALIS study was approved but First Subject In has not been achieved in any participating countries therefore no summary of study results will be submitted. The Sponsor's overall assessment of the program did not support initiation of the study. This decision was not based on the grounds of safety.

Sincerely,



Global Clinical Head, Fasenra